macro

Summit Therapeutics: FDA cannot approve ivonescimab BLA without significant OS gain

Summit Therapeutics said the FDA cannot approve the ivonescimab application due to no significant overall survival gain, though its PFS endpoint improved.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

According to Reuters, Summit Therapeutics said the US Food and Drug Administration cannot approve its biologics license application for ivonescimab. The reason is the lack of a statistically significant improvement in overall survival (OS).

The company noted that the Phase III HARMONI study showed a statistically significant improvement in progression-free survival (PFS). It also reported an acceptable safety profile for ivonescimab combined with chemotherapy. The drug is being developed in Phase II/III trials for non-small cell lung cancer, colorectal cancer, ulcerative colitis and renal cell carcinoma.

Summit is also collaborating with AstraZeneca and Daiichi Sankyo on ivonescimab combinations.

why it matters

For Summit shares, the regulatory refusal means a delay to bringing the drug to market and uncertainty over commercialization timing. Investors will watch how the company addresses the OS results in further studies.

market impact

Summit Therapeutics shares: FDA refusal without significant OS gain weighs on the stock

  • Summit Therapeutics (SMMT) pressure down — the regulator cannot approve the BLA without a significant OS improvement

tags

instruments

SMMTAstraZenecaDaiichi Sankyo

sources

  1. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application — Reuters, 15 November 2026 at 12:03 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗